Catalogo dei prodotti della ricerca

MARTELLI, Maurizio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.028
EU - Europa 3.192
AS - Asia 1.828
AF - Africa 48
SA - Sud America 44
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.158
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.904
IT - Italia 1.533
SG - Singapore 737
SE - Svezia 489
IN - India 482
CN - Cina 434
UA - Ucraina 332
FI - Finlandia 235
DE - Germania 121
CA - Canada 115
GB - Regno Unito 115
RO - Romania 78
BG - Bulgaria 68
IE - Irlanda 47
TR - Turchia 41
NL - Olanda 34
TG - Togo 34
AR - Argentina 32
ID - Indonesia 29
JP - Giappone 25
TH - Thailandia 25
BE - Belgio 20
FR - Francia 20
RU - Federazione Russa 18
GR - Grecia 17
AU - Australia 14
KR - Corea 13
ES - Italia 12
CH - Svizzera 11
HK - Hong Kong 10
ZA - Sudafrica 10
HR - Croazia 8
BR - Brasile 7
MX - Messico 7
AT - Austria 5
CL - Cile 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
PT - Portogallo 4
VN - Vietnam 4
AZ - Azerbaigian 3
BD - Bangladesh 3
HU - Ungheria 3
KZ - Kazakistan 3
MK - Macedonia 3
MY - Malesia 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
EU - Europa 2
IL - Israele 2
IR - Iran 2
JM - Giamaica 2
JO - Giordania 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PK - Pakistan 2
AM - Armenia 1
EG - Egitto 1
IQ - Iraq 1
LI - Liechtenstein 1
LU - Lussemburgo 1
NG - Nigeria 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 14.158
Salva come PNG Salva come JPEG
Città #
Fairfield 1.248
Woodbridge 771
Chandler 606
Rome 584
Ashburn 568
Singapore 524
Houston 500
Seattle 486
Dearborn 455
Wilmington 404
Cambridge 398
Ann Arbor 372
Princeton 291
Plano 224
Santa Clara 213
Lawrence 200
Boston 191
Beijing 150
Jacksonville 142
San Paolo di Civitate 123
Millbury 97
San Diego 96
Andover 69
Sofia 68
Milan 67
Des Moines 63
New York 52
Toronto 51
Dublin 46
Norwalk 42
Falls Church 40
Boardman 37
Istanbul 36
Lomé 34
Ottawa 34
Hefei 32
Federal 29
Nanjing 29
Jakarta 28
Mannheim 28
San Mateo 27
Bangkok 25
Southend 23
Bremen 22
Bühl 22
Guangzhou 21
Kunming 21
Brussels 20
Los Angeles 20
Bologna 17
Helsinki 17
Phoenix 17
Lappeenranta 16
Florence 15
Indiana 15
Falkenstein 11
Nanchang 11
Naples 11
Stockholm 11
Padova 10
Redmond 10
Sydney 10
Vancouver 10
Catanzaro 9
Chieuti 9
Jinan 9
Prineville 9
Auburn Hills 8
Dallas 8
London 8
Muizenberg 8
Redwood City 8
Saint Petersburg 8
Salerno 8
Trumbull 8
Zagreb 8
Amsterdam 7
Brescia 7
Buffalo 7
Como 7
Napoli 7
Turin 7
Fiesole 6
Fort Worth 6
Fremont 6
Hong Kong 6
Montreal 6
Nettuno 6
Shenyang 6
Squamish 6
Viareggio 6
Aprilia 5
Aversa 5
Bari 5
Chicago 5
Colchester 5
Edinburgh 5
Genoa 5
Las Vegas 5
Leawood 5
Totale 10.059
Salva come PNG Salva come JPEG
Nome #
Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario 268
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study 185
MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. 110
EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP 108
Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non Hodgkin aggressivo 107
Pulmonary mycobacteriosis in a patient affected by mycosis fungoides: a diagnostic and therapeutic challenge. 101
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma 101
Efficacy and safety of long term tenofovir in high risk patients with hematological malignancies (HM) to prevent Hepatitis B Virus (HBV) reactivation after immunosuppressive therapies in real life 97
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review 95
Primary mediastinal large B-cell lymphoma 92
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 89
A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAIPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-DENSE CHEMOTHERAPY CHOP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL) 89
Expression of p53 and retinoblastoma gene in high-grade nodal peripheral T-cell lymphomas: Immunohistochemical and molecular findings suggesting different pathogenetic pathways and possible clinical implications 88
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high- dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). 87
A case of Burkitt lymphoma-L3 ALL with t(8;14)translocation, developed 10 years after Hodgkin's disease. 86
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial 85
Primary mediastinal lymphoma: diagnosis and treatment options. 85
Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19 84
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 82
Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? 81
SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. 81
NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey 80
Surgery in primary gastric lymphoma: impact on clinical staging and long-term survival. 80
Cytological diagnostic features of late breast implant seromas. From reactive to anaplastic large cell lymphoma 80
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation 80
Primary mediastinal large B-cell lymphoma 80
B-cell acute lymphoid leukemia (ALL) with lymphoblasts expressing surface immunoglobulins only at relapse. 79
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma 79
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. 78
Feasibility and results of a multimodality approach in elderly patients with localized intermediate to high-grade non-Hodgkin's lymphomas 78
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 78
Nongastrointestinal Low- Grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 78
Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients 78
MACOP-B vs F-MACHOP: Regimen in the treatment of high-grade non Hodgkin's Lymphomas. 77
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. 77
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. 77
Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL) 77
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases 76
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology 75
Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy 75
Delayed cutaneous hypersensivity (DCH) in 92 acute leukemia patients: retrospective study considering clinical and prognostic parameters. 75
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma 75
ANAPLASTIC LARGE-CELL LYMPHOMA (CD30+/KI-1+) - RESULTS OF A PROSPECTIVE CLINICOPATHOLOGICAL STUDY OF 69 CASES 75
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma 74
Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. 74
Corrigendum to "Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept: A case report and literature review" [Leuk. Res. 36 (2012) e199-e201] 74
Primary mediastinal large B-cell lymphoma 74
Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas 73
Long-lasting remission of a relapsed large cell non-Hodgkin's lymphoma by Y90 ibritumomab tiuxetan as salvage therapy 72
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 72
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients 71
The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma) 71
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma 71
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) 71
Thymoma: a clinico-pathologic study based on newly developed morphologic criteria 71
pathogenetic and clinical implications of bcl-6 and bcl-2 gene configuration in nodal diffuse large B-cell lymphomas 71
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 70
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper 70
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma 70
Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy 69
Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 69
PROGNOSIS IN CHRONIC LYMPHOCYTIC-LEUKEMIA - A RETROSPECTIVE MULTICENTRIC STUDY FROM THE GIMEMA GROUP 69
A MALT lymphoma prognostic index 69
Local hyperthermia and radiation therapy in the treatment of superficially located lymphomas and recurrent Hodgkin's disease 69
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. 69
Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma. 68
Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply 67
Current guidelines for the management of aggressive non-Hodgkin's lymphoma 66
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 66
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): Final results of a multicentre, open-label, randomised, controlled, phase 3 study 66
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 65
F-MACHOP IN ADVANCED AGGRESSIVE LYMPHOMA 64
MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis 64
A GENETIC VARIANT OF MLH1, A GENE INVOLVED IN DNA MISMATCH REPAIR, IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP 64
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation 64
A predictive model for limited stage diffuse large B-cell lymphoma (DLBCL): A retrospective analysis of 1,252 cases performed by the Intergruppo Italiano Linfomi (IIL) 64
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy 64
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 64
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. 64
Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. 64
A Phase II Trial of Rituximab-CHOP Chemotherapy Followed by Yttrium 90 (Y-90) Ibritumomab Tiuxetan (Y-90-IT) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients 63
The Genotype of MLH1 Is An Independent Predictor of Outcome In Diffuse Large B-Cell Lymphoma Treated with R-CHOP: a Training-Validation Study 63
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project 62
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group 62
Impact of dose-dense immunochemotherapy on prognosis of germinal center and non germinal center origin of diffuse large B cell lymphoma. 61
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study 61
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. 61
R-CHOP vs R-MiniCEOP in elderly patients with diffuse large B-cell lymphoma (B-DLCL) prospectively selected by a multidimensional evaluation scale: Preliminary results of a Randomized study performed by Intergruppo Italiano Linfomi (IIL) 61
Intrathoracic lobe of the liver. Case report and review of the literature 60
Diffuse large B-cell lymphoma. 60
Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study 60
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups) 58
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. 58
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma 57
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy. results from a monoinstitutional cohort analysis of long-term survivors 57
Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study 56
Successful resection of a thymoma in an elderly patient 55
Prognostic value of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). 55
High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. 55
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 55
Totale 7.625
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.688
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.397 0 0 0 0 249 643 489 331 291 210 96 88
2020/20211.066 119 118 28 72 38 180 25 114 91 150 74 57
2021/20222.642 28 121 239 140 356 101 44 248 203 227 366 569
2022/20232.431 539 516 94 250 227 245 70 164 168 43 87 28
2023/20241.544 76 177 92 114 112 183 68 92 30 229 153 218
2024/20251.350 183 275 330 268 294 0 0 0 0 0 0 0
Totale 14.660